Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab / 대한내과학회지
Korean Journal of Medicine
; : 415-418, 2017.
Article
em En
| WPRIM
| ID: wpr-211162
Biblioteca responsável:
WPRO
ABSTRACT
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Prognóstico
/
Radioterapia
/
Doença de Hodgkin
/
Tratamento Farmacológico
/
Elétrons
/
Febre
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
Tipo de estudo:
Prognostic_studies
Limite:
Adolescent
/
Humans
/
Male
Idioma:
En
Revista:
Korean Journal of Medicine
Ano de publicação:
2017
Tipo de documento:
Article